Therapeutic considerations for severe nodular acne

American Journal of Clinical Dermatology

Volumn 12, Issue 1, 2011, Pages 7-14

  Newman, Marissa D ^a   Bowe, Whitney P ^b   Heughebaert, Carol ^b   Shalita, Alan R ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b SUNY Downstate Medical Center   (United States)

Author keywords

Acne, treatment; Adapalene, therapeutic use; Antiandrogens, therapeutic use; Antibacterials, therapeutic use; Benzoyl peroxide, therapeutic use; Corticosteroids, therapeutic use; Cyproterone, therapeutic use; Doxycycline, therapeutic use; Isotretinoin, therapeutic use; Minocycline, therapeutic use; Nodulocystic acne, treatment; Oral contraceptives, therapeutic use; Oxytetracycline, therapeutic use; Retinoids, therapeutic use; Spironolactone, therapeutic use; Tazarotene, therapeutic use; Tetracycline, therapeutic use; Tetracyclines, therapeutic use; Tretinoin, therapeutic use

Indexed keywords

ADAPALENE; AZITHROMYCIN; BENZOYL PEROXIDE; CLINDAMYCIN; CORTICOSTEROID; CYPROTERONE ACETATE; DEXAMETHASONE; DOXYCYCLINE; DROSPIRENONE; ERYTHROMYCIN; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; ISOTRETINOIN; LEVONORGESTREL; MINOCYCLINE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; OXYTETRACYCLINE; PREDNISONE; RETINOIC ACID; RETINOID; SPIRONOLACTONE; TAZAROTENE; TETRACYCLINE;

ACNE; ANDROGEN DEPRIVATION THERAPY; ANTIBIOTIC RESISTANCE; ARTHRALGIA; AUTOIMMUNE DISEASE; BACTERIAL COLONIZATION; BIRTH DEFECT; BLOOD EXAMINATION; COMEDO; CONTROLLED DRUG RELEASE; CREAM; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRY NOSE; DYSMENORRHEA; ERYTHEMA; GASTROINTESTINAL SYMPTOM; GEL; HEADACHE; HEPATITIS; HORMONAL THERAPY; HUMAN; HYPERKALEMIA; HYPEROSTOSIS; HYPERPIGMENTATION; HYPOPIGMENTATION; INTRACRANIAL HYPERTENSION; LOW DRUG DOSE; MASTALGIA; MONOTHERAPY; MUCOSAL DRYNESS; MYALGIA; PANCREATITIS; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PSYCHOSIS; REVIEW; SEBACEOUS GLAND; SEBUM; SKIN SCAR; SUICIDE; URTICARIA; VAGINA CANDIDIASIS; VERTIGO; XEROSIS;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CICATRIX; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 78649660805     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11532280-000000000-00000     Document Type: Review

References (88)

1. Shalita AR. Acne: clinical presentations. Clin Dermatol 2004 Sep-Oct; 22 (5): 385-6
2. Shalita AR, Myers JA, Krochmal L, et al. The safety and efficacy of clinda-mycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol 2005 Jan-Feb; 4 (1): 48-56
3. Bolognia J, Jorizzo J, Rapini R, editors. Dermatology. Philadelphia (PA): Mosby; 2003
4. Pochi PE, Shalita AR, Strauss JS, et al. Report of the consensus conference on acne classification: Washington, DC, March 24 and 25, 1990. J Am Acad Dermatol 1991 Mar; 24 (3): 495-500
5. Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. Phila-delphia (PA): Mosby Elsevier, 2008
6. Farber EM, Claiborne ER. Acne conglobata; use of cortisone and cortico-tropin in therapy. Calif Med 1954 Aug; 81 (2): 76-8
7. Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol 1999 Aug; 141 (2): 307-9
8. Jansen T, Plewig G, Kligman AM. Diagnosis and treatment of rosacea ful-minans. Dermatology 1994; 188 (4): 251-4
9. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003 Jul; 49 (1 Suppl.): S1-37
10. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004 Aug 11; 292 (6): 726-35
11. Thiboutot D, Gollnick H, Bettoli V, et al., Global Alliance to Improve Out-comes in Acne. New insights into the managementof acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009 May; 60 (5 Suppl.): S1-50
12. Oberemok SS, Shalita AR. Acne vulgaris: I. Pathogenesis and diagnosis. Cutis 2002 Aug; 70 (2): 101-5
13. Layton AM, Seukeran D, Cunliffe WJ. Scarred for life? Dermatology 1997; 195 Suppl. 1: 15-21; discussion 38-40
14. Holland DB, Jeremy AH, Roberts SG, et al. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol 2004 Jan; 150 (1): 72-81
15. Eady EA. Bacterial resistance in acne. Dermatology 1998; 196 (1): 59-66
16. Katsambas A, Papakonstantinou A. Acne: systemic treatment. Clin Dermatol 2004 Sep-Oct; 22 (5): 412-8
17. Dreno B, Bettoli V, Ochsendorf F, et al. An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur J Dermatol 2006 Sep-Oct; 16 (5): 565-71
18. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 43-9
19. Leyden JJ. The role of isotretinoin in the treatment of acne: personal ob-servations. J Am Acad Dermatol 1998 Aug; 39 (2 Pt 3): S45-9
20. Goulden V, Layton AM, Cunliffe WJ. Current indications for isotretinoin as a treatment for acne vulgaris. Dermatology 1995; 190 (4): 284-7
21. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 2002 Apr; 46 (4): 505-9
22. Layton AM, Knaggs H, Taylor J, et al. Isotretinoin for acne vulgaris: 10 years later: a safe and successful treatment. Br J Dermatol 1993 Sep; 129 (3): 292-6
23. Shalita AR, Cunningham WJ, Leyden JJ, et al. Isotretinoin treatment of acne and related disorders: an update. J Am Acad Dermatol 1983 Oct; 9 (4): 629-38
24. Cunliffe WJ, van de Kerkhof PC, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194 (4): 351-7
25. Dhir R, Gehi NP, Agarwal R, et al. Oral isotretinoin is as effective as a com-binationoforal isotretinoin and topical anti-acne agents in nodulocystic acne. Indian J Dermatol Venereol Leprol 2008 Mar-Apr; 74 (2): 187
26. Alestas T, Ganceviciene R, Fimmel S, et al. Enzymes involved in the biosyn-thesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med 2006 Jan; 84 (1): 75-87
27. Demircay Z, Kus S, Sur H. Predictive factors for acne flare during isotretinoin treatment. Eur J Dermatol 2008 Jul-Aug; 18 (4): 452-6
28. Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992 Dec; 27 (6 Pt 2): S2-7
29. Stainforth JM, Layton AM, Taylor JP, et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993 Sep; 129 (3): 297-301
30. Goulden V, Layton AM, Cunliffe WJ. Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol 1994 Sep; 131 (3): 360-3
31. McLane J. Analysis of common side effects of isotretinoin. J Am Acad Der-matol 2001 Nov; 45 (5): S188-94
32. Halpagi P, Grigg J, Klistorner A, et al. Night blindness following low-dose isotretinoin. J Eur Acad Dermatol Venereol 2008 Jul; 22 (7): 893-4
33. Ellies P, Dighiero P, Legeais JM, et al. Persistent corneal opacity after oral isotretinoin therapy for acne. Cornea 2000 Mar; 19 (2): 238-9
34. Gerber LH, Helfgott RK, Gross EG, et al. Vertebral abnormalities associated with synthetic retinoid use. J Am Acad Dermatol 1984 May; 10 (5 Pt 1): 817-23
35. Kilcoyne RF, Cope R, Cunningham W, et al. Minimal spinal hyperostosis with low-dose isotretinoin therapy. Invest Radiol 1986 Jan; 21 (1): 41-4
36. Griffin JP. A review of the literature on benign intracranial hypertension associated with medication. Adverse Drug React Toxicol Rev 1992; 11 (1): 41-57
37. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Der-matol 2000 Oct; 136 (10): 1231-6
38. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2005 Jun; 24 (2): 92-102
39. Schaefer C, Meister R, Weber-Schoendorfer C. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet 2010 Feb; 281 (2): 221-7
40. Cheetham TC, Wagner RA, Chiu G, et al. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol 2006 Sep; 55 (3): 442-8
41. Weinberg JM. iPLEDGE allegiance. Cutis 2005 Dec; 76 (6): 356
42. Dai WS, Hsu MA, Itri LM. Safety of pregnancy after discontinuation of iso-tretinoin. Arch Dermatol 1989 Mar; 125 (3): 362-5
43. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995 Jul 13; 333 (2): 101-6
44. Hendrix CW, Jackson KA, Whitmore E, et al. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethin-drone. Clin Pharmacol Ther 2004 May; 75 (5): 464-75
45. Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology 2002; 204 (3): 232-5
46. Baxter KF, Ling TC, Barth JH, et al. Retrospective survey of serum lipids in patients receiving more than three courses of isotretinoin. J Dermatolog Treat 2003 Dec; 14 (4): 216-8
47. Tan HH. Antibacterial therapy for acne: a guide to selection and use of sys-temic agents. Am J Clin Dermatol 2003; 4 (5): 307-14
48. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007 Apr; 56 (4): 651-63
49. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2003; (1): CD002086
50. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2000; (2): CD002086
51. Stewart DM, Torok HM, Weiss JS,etal. Dose-ranging efficacyofnew once-daily extended-release minocycline for acne vulgaris. Cutis 2006 Oct; 78 (4 Suppl.): 11-20
52. Plott RT, Wortzman MS. Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. Cutis 2006 Oct; 78 (4 Suppl.): 6-10
53. Hubbell CG, Hobbs ER, Rist T, et al. Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Arch Dermatol 1982 Dec; 118 (12): 989-92
54. Fleischer Jr AB, Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline. Cutis 2006 Oct; 78 (4 Suppl.): 21-31
55. Extended-release minocycline (Solodyn) for acne. Med Lett Drugs Ther 2006 Nov 20; 48 (1248): 95-6
56. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline: report of 13 patients and review of the literature. Arch Dermatol 1996 Aug; 132 (8): 934-9
57. Liao DC. Management of acne. J Fam Pract 2003 Jan; 52 (1): 43-51
58. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007 Jun; 79 (6 Suppl.): 9-25
59. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a world-wide problem. Dermatology 2003; 206 (1): 54-6
60. Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibac-teria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989 Jul; 121 (1): 51-7
61. Margolis DJ, Bowe WP, Hoffstad O, et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005 Sep; 141 (9): 1132-6
62. Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and-resistant skin bacteria from acne patients. Br J Dermatol 1994 Sep; 131 (3): 331-6
63. Dreno B, BettoliV, Ochsendorf F, etal. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004 Nov-Dec; 14 (6): 391-9
64. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin 2007 Apr; 25 (2): 127-32, v
65. Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a com-bination of benzoyl peroxide and erythromycin on skin carriage of erythro-mycin-resistant propionibacteria. Br J Dermatol 1996 Jan; 134 (1): 107-13
66. Mills Jr OH, Kligman AM, Pochi P, et al. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986 Dec; 25 (10): 664-7
67. Fanta D, Muller MM. Effect of benzoyl peroxide on skin surface lipids. Dermatologica 1979; 158 (1): 55-9
68. Chalker DK, Shalita A, Smith Jr JG, et al. A double-blind study of the effec-tiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983 Dec; 9 (6): 933-6
69. Tschen EH, Katz HI, Jones TM, et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis 2001 Feb; 67 (2): 165-9
70. Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007 Nov; 57 (5): 791-9
71. Bowman S, Gold M, Nasir A, et al. Comparison of clindamycin/benzoyl per-oxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J Drugs Dermatol 2005 Sep-Oct; 4 (5): 611-8
72. Leyden JJ. Topical treatment of acne vulgaris: retinoids and cutaneous irrita-tion. J Am Acad Dermatol 1998 Apr; 38 (4): S1-4
73. Thielitz A, Abdel-Naser MB, Fluhr JW, et al. Topical retinoids in acne: an evidence-based overview. J Dtsch Dermatol Ges 2008 Dec; 6 (12): 1023-31
74. Jain S. Topical tretinoin or adapalene in acne vulgaris: an overview. J Dermatolog Treat 2004 Jul; 15 (4): 200-7
75. Kligman AM. How to use topical tretinoin in treating acne. Cutis 1995 Aug; 56 (2): 83-4
76. Leyden JJ, Grossman R, Nighland M. Cumulative irritation potential of top-ical retinoid formulations. J Drugs Dermatol 2008 Aug; 7 (8 Suppl.): s14-8
77. Beylot C, Doutre MS, Beylot-Barry M. Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology 1998; 196 (1): 148-52
78. Palombo-Kinne E, Schellschmidt I, Schumacher U, et al. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2mg di-enogest for the treatment of papulopustular acne in comparison with placebo and 0.035mg ethinylestradiol/2mg cyproterone acetate. Contraception 2009 Apr; 79 (4): 282-9
79. Johnson BA, Nunley JR. Use of systemic agents in the treatment of acne vulgaris. Am Fam Physician 2000 Oct 15; 62 (8): 1823-30, 1835-6
80. Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997 Jan; 136 (1): 66-70
81. Diamanti-Kandarakis E. Current aspects of antiandrogen therapy in women. Curr Pharm Des 1999 Sep; 5 (9): 707-23
82. Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have poly-cystic ovaries. Br J Dermatol 1989 Dec; 121 (6): 675-80
83. Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of poly-cystic ovary syndrome in women with acne. J Dermatol 1997 Apr; 24 (4): 223-9
84. Lucky AW, Henderson TA, Olson WH, etal. Effectivenessofnorgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997 Nov; 37 (5 Pt 1): 746-54
85. Thiboutot DM. Endocrinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 57-61
86. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol 2010 Jan-Feb; 28 (1): 17-23
87. Levine RM, Rasmussen JE. Intralesional corticosteroids in the treatment of nodulocystic acne. Arch Dermatol 1983 Jun; 119 (6): 480-1
88. Mahajan BB, Garg G. Therapeutic efficacy of intralesional triamcinolone acetonide versus intralesional triamcinolone acetonide plus lincomycin in the treatment of nodulocystic acne. Indian J Dermatol Venereol Leprol 2003 May-Jun; 69 (3): 217-9